Evidence map›Paper›PMID 32601092›Full record

ArticleBMJ global health2020

The reactive vaccination campaign against cholera emergency in camps for internally displaced persons, Borno, Nigeria, 2017: a two-stage cluster survey.

Moise Chi Ngwa, Wondimagegnehu Alemu, Ifeanyi Okudo, Collins Owili, Uzoma Ugochukwu, Peter Clement, Isabelle Devaux, Lorenzo Pezzoli, James Agada Oche, Chikwe Ihekweazu and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cholera in Nigeria: A review of outbreaks, trends, contributing factors, and public health responses.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Moise Chi NgwaInternational Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA ngwaadangfor@gmail.com.ORCID 0000-0002-1359-6267
Wondimagegnehu AlemuWHO, Nigeria Country Office, Abuja, Nigeria.
Ifeanyi OkudoWHO, Nigeria Country Office, Abuja, Nigeria.
Collins OwiliWHO, Nigeria Country Office, Abuja, Nigeria.ORCID 0000-0001-8001-6878
Uzoma UgochukwuWHO, Nigeria Country Office, Abuja, Nigeria.
Peter ClementWHO, Nigeria Country Office, Abuja, Nigeria.
Isabelle DevauxWHO Country Office, Maiduguri, Nigeria.
Lorenzo PezzoliWHO, Geneve, Switzerland.
James Agada OcheWHO, Nigeria Country Office, Abuja, Nigeria.
Chikwe IhekweazuNigeria Centre for Disease Control, Abuja, Nigeria.
David A SackInternational Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9338-5119
World Health Organization - Nigeria · NGJohns Hopkins University · USNigeria Centre for Disease Control · NGUniversity of Maiduguri · NG

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Epidemiology and Ecology of Cholera in AfricaR01AI123422 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Amanda Kay Debes, DAVID A SACK · 2017 to 2026
$6.6M
NCATS NIH HHS UL1 TR001079NIAID NIH HHS R01 AI123422World Health Organization 001
6 · The paper itself

Abstract

introductionIn 2017, amidst insecurity and displacements posed by Boko Haram armed insurgency, cholera outbreak started in the Muna Garage camp for Internally Displaced Persons (IDPs) in Borno State, Nigeria. In response, the Borno Ministry of Health and partners determined to provide oral cholera vaccine (OCV) to about 1 million people in IDP camps and surrounding communities in six Local Government Areas (LGAs) including Maiduguri, Jere, Konduga, Mafa, Dikwa, and Monguno. As part of Monitoring and Evaluation, we described the coverage achieved, adverse events following immunisation (AEFI), non-vaccination reasons, vaccination decisions as well as campaign information sources.

methodsWe conducted two-stage probability cluster surveys with clusters selected without replacement according to probability-proportionate-to-population-size in the six LGAs targeted by the campaign. Individuals aged ≥1 years were the eligible study population. Data sources were household interviews with vaccine card verification and memory recall, if no card, as well as multiple choice questions with an open-ended option.

resultsOverall, 12 931 respondents participated in the survey. Overall, 90% (95% CI: 88 to 92) of the target population received at least one dose of OCV, range 87% (95% CI: 75 to 94) in Maiduguri to 94% (95% CI: 88 to 97) in Monguno. The weighted two-dose coverage was 73% (95% CI: 68 to 77) with a low of 68% (95% CI: 46 to 86) in Maiduguri to a high of 87% (95% CI: 74 to 95) in Dikwa. The coverage was lower during first round (76%, 95% CI: 71 to 80) than second round (87%, 95% CI: 84 to 89) and ranged from 72% (95% CI: 42 to 89) and 82% (95% CI: 82 to 91) in Maiduguri to 87% (95% CI: 75 to 95) and 94% (95% CI: 88 to 97) in Dikwa for the respective first and second rounds. Also, coverage was higher among females of age 5 to 14 and ≥15 years than males of same age groups. There were mild AEFI with the most common symptoms being fever, headache and diarrhoea occurring up to 48 hours after ingesting the vaccine. The most common actions taken after AEFI symptoms included 'did nothing' and 'self-medicated at home'. The top reason for taking vaccine was to protect from cholera while top reason for non-vaccination was travel/work. The main source of campaign information was a neighbour. An overwhelming majority (96%, 95% CI: 95% to 98%) felt the campaign team treated them with respect. While 43% (95% CI: 36% to 50%) asked no questions, 37% (95% CI: 31% to 44%) felt the team addressed all their concerns.

conclusionThe campaign achieved high coverage using door-to-door and fixed sites strategies amidst insecurity posed by Boko Haram. Additional studies are needed to improve how to reduce non-vaccination, especially for the first round. While OCV provides protection for a few years, additional actions will be needed to make investments in water, sanitation and hygiene infrastructure.

Indexed as

CholeraRefugeesAdolescentChildChild, PreschoolFemaleHumansImmunization ProgramsMaleNigeriaSurveys and Questionnairescholeracross-sectional surveypublic healthvaccines

Identifiers

PMID32601092
PMCPMC7326259
OpenAlexW3037905784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.